Leprosy. Recognition and treatment

Area of Science:

• Infectious Diseases
• Dermatology
• Neurology

Background:

• Leprosy, caused by Mycobacterium leprae, is a chronic infectious disease affecting skin and nerves.
• It is a stigmatizing condition prevalent in tropical and subtropical regions, necessitating early detection and treatment for control.
• Leprosy presents with diverse clinical forms, including indeterminate, lepromatous, and tuberculoid.

Purpose of the Study:

• To emphasize the critical role of early diagnosis and prompt therapy in managing leprosy.
• To highlight the importance of recognizing initial disease phases to prevent severe manifestations.
• To underscore the need for increased awareness among healthcare workers and populations in endemic areas.

Main Methods:

• Diagnosis relies on clinical presentation, supplemented by skin bacilloscopy and histopathology.
• Current treatment involves multidrug therapy (MDT) with rifampicin, clofazimine, and dapsone.
• Therapy duration has been reduced to 12 months, with new drug combinations under evaluation.

Main Results:

• Multidrug therapy effectively eliminates M. leprae and prevents resistance.
• Reduced treatment duration to 12 months enhances patient compliance and outcomes.
• Newer treatment regimens show promise for specific leprosy forms, such as paucibacillary leprosy.

Conclusions:

• Early diagnosis and intervention are paramount to preventing severe leprosy complications and reducing its public health burden.
• Increased awareness and recognition of early leprosy signs among healthcare providers and the public are essential.
• Continued research into novel therapeutic strategies is vital for improving leprosy control efforts worldwide.